Atria Senior Living: COVID-19 testing protects the most vulnerable - Insights
When most of the world was still struggling to understand how COVID-19 would affect their lives, Atria Senior Living took steps to protect their vulnerable residents and staff.
Mayo Clinic Labs @Work: Rehab Elkadri - Insights
Rehab Elkadri joined Mayo Clinic Laboratories in December 2021, relocating from the United Kingdom to the United Arab Emirates. As an international clinical specialty liaison in the Neurology division for the Middle East and North Africa...
MCL @Work: Becca Johnson - Insights
Becca Johnson, a dedicated project manager, joined Mayo Clinic in 2014, driven by a desire to contribute to an organization making a global impact. With BioPharma Diagnostics, Becca oversees large projects, ensuring efficient sample...
MCL @Work: Adam Stewart - Insights
In spring of 2022, Adam Stewart joined Mayo Clinic’s Blood Donor Program as a marketing and recruitment coordinator. He enjoys and finds great purpose in his work because he loves to see members of his local community donate blood and help...
Membranous nephropathy assay: PMND1 - Insights
John Lieske, M.D., describes Mayo Clinic Laboratories' new test for primary membranous nephropathy. PMND1 is a diagnostic cascade that provides a cost-effective approach to detecting antigens known to cause membranous nephropathy — a...
Assay finds genetic cause of low bile flow: Devin Oglesbee, Ph.D. - Insights
Devin Oglesbee, Ph.D., explains how Mayo Clinic Laboratories' cholestasis gene panel identifies mutations that cause low flow of bile from the liver. Test results help guide treatment decisions that can prevent liver damage.
IDH assay facilitates timelier leukemia treatment: Rong He, M.D. - Insights
In this test-specific episode of the "Answers From the Lab" podcast, Rong He, M.D., explains how Mayo Clinic Laboratories' IDHQ test improves upon next generation sequencing for assessing AML treatment options.
FDA-approved test expands options for Alzheimer's disease - Insights
Joshua Bornhorst, Ph.D., describes the new, FDA-approved Alzheimer's disease (AD) test and how it differs from Mayo Clinic Laboratories' existing AD evaluation. The laboratory will offer both tests, to ensure flexibility and options for...
PIK3CA assay guides treatment of progressing breast cancer - Insights
Katherine Geiersbach, M.D., explains how Mayo Clinic Laboratories' PIK3CA assay informs breast cancer treatment. The assay identifies patients eligible for a certain second-line therapy when initial treatment has failed.
Chromium and Cobalt - Insights
Paul Jannetto, Ph.D., describes Mayo Clinic Laboratories' synovial fluid testing for patients with symptoms of failed hip arthroplasty. The Food and Drug Administration recommends testing for elevated chromium and cobalt, which can indicate...